TWI768781B - TRANSFORMING GROWTH FACTOR-β RECEPTOR INHIBITOR - Google Patents

Abstract

The present invention provides a compound of formula (I) and a pharmaceutical composition thereof. The compound of formula (I) of the present invention can be used as TGF-β receptor inhibitors, especially TGFβRI inhibitors, and can be used to prevent or treat, for example, various related diseases mediated by TGFβRI (ALK5).

Description

Transforming growth factor-beta receptor inhibitor

The present invention provides a new type of heterocyclic compound, its preparation method and its application as a TGF-beta receptor (especially TGFbetaRI) antagonist.

Transforming growth factor-β (TGF-β) is a multifunctional growth factor and cytokine, which is closely related to activins, inhibins, and Mullerian inhibitor substances. , MIS) and bone morpho-genetic proteins (BMPs) and other related proteins constitute the transforming growth factor-β superfamily. It is involved in the regulation of a variety of biological processes, including cell proliferation, differentiation, development, and modification of the extracellular matrix (including tumor stroma and immunosuppression, angiogenesis, and fibrogenesis).

There are three main cellular receptors for TGF-β, namely type I (TGFβRI), type II (TGFβRII) and type III (TGFβRIII). Signal transduction in the TGF-β signaling pathway is mainly through the binding of TGF-β ligands to the serine/threonine kinase receptors TGFβRI (ALK5) and TGFβRII on the cell surface to form a heterotetrameric complex, and then TGFβRII interacts with TGFβRI. The glycine/serine region (GS region) of TGFβRI phosphorylates and initiates the phosphorylation of TGFβRI to the intracellular signaling protein Smad protein molecule - Smad2/Smad3. The complexes formed by phosphorylated Smad2 and Smad3 proteins combined with Smad4 are translocated to the nucleus, where they bind to different transcription factors and transcriptional co-initiators or co-repressors to regulate the transcription of target genes and cause a variety of transcriptional responses, resulting in Changes in gene expression. The transforming growth factor-β type III receptor (TGFβRIII) itself cannot transmit signals, but it can bind TGF-β and Delivered to TGFβRII to enhance the binding of TGF-β ligands to TGF-β type II receptors, thereby indirectly affecting signal transduction. In vivo, cytokines, growth factors, microenvironmental conditions, hormones, phosphorylation and dephosphorylation kinases, etc. can all affect and control the signal transduction in the TGF-β signaling pathway.

Studies have shown that TGF-β plays a key role in the occurrence and progression of fibrosis in different organ systems such as the heart, liver, lung, and kidney. Aberrant TGF-β signaling has been implicated in many human diseases, such as cancer, cardiovascular disease, inflammation, organ fibrosis, and pancreatic disease. Dysregulation of TGF-β signaling is common in human tumors, promoting tumor cell growth and differentiation, and regulating the extracellular matrix and epithelial-mesenchymal transition. At present, with the deepening of tumor immunotherapy research, TGF-β has been confirmed to play an important role in regulating anti-tumor immunity. TGF-β has a strong inhibitory effect on the differentiation of T lymphocytes, and has a significant negative effect on dendritic cells, CD8 ⁺ T cells and NK cells, and it can enhance immunosuppressive T _reg and myeloid-derived suppressor cells (Myeloid cells). -derived suppressor cells, MDSCs), thereby providing a favorable tumor microenvironment for tumor growth and metastasis. Therefore, inhibiting the signal transduction of a certain link in the TGF-β signaling pathway may become one of the effective methods for the treatment of tumors.

TGFβRI (ALK5), as an important node in the TGF-β signaling pathway, is considered to be an important target for tumor therapy. By preventing the binding of TGFβRI to ligands, it inhibits the phosphorylation of ALK5 to its downstream signaling proteins (Smad2 or Smad3). Therefore, it can affect or block the transduction of TGF-β signaling to achieve the prevention and treatment of various related diseases mediated by ALK5.

目前，國際專利申請公開號WO2000/061576、WO2002/066462、WO2004/111036、WO2004/048382、WO2009/087224、WO2009/013335、WO2012/002680、WO2016/057278、WO2017/015425、WO2017/215506、WO2018/017633 et al. and Chinese Patent Application Publication No. CN107663206A et al. disclose compounds useful as TGF-beta receptor antagonists. However, there is still a need for better inhibitory effects on TGF-β receptors, especially TGFβRI (ALK5) In particular, antagonists that can selectively inhibit ALK5 have important clinical value and therapeutic significance, but there are few reports on them. In the prior art, there is an urgent need for ALK5 inhibitors with better inhibitory effect, especially novel antagonist compounds capable of selectively inhibiting ALK5.

After long-term and in-depth research, we unexpectedly discovered a class of heterocyclic compounds with good ALK5 inhibitory activity.

Based on the above findings, in a first aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt, prodrug, isotopic derivative, isomer, solvate, or metabolite thereof,

in:

Cy represents a C ₆ -C ₁₀ aryl group or a 5-10-membered heteroaryl group substituted by 0, 1, 2 or 3 substituents, wherein the substituents are selected from: halogen, C ₁ -C ₆ alkyl , C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , - C(O)OR ^a , -C(O)NR ^a R ^b , -P(O)R ^a R ^b ;

R ¹ represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, hydroxy (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl;

R ² represents hydrogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, hydroxy (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, Nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -NR ^a C(O)R ^b , -SO ₂ NR ^a R ^b , -NR ^a SO ₂ R ^b ;

R ³ represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, hydroxy (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano group, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -NR ^a C(O)R ^b , -SO ₂ NR ^a R ^b , -NR ^a SO ₂ R ^b ;

R ⁴ represents hydrogen, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , hydroxyl (C ₁ -C ₆ alkyl); R ⁵ represents hydrogen, C ₁ -C ₆ alkyl, C ₂ - C ₆ alkene group, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl; or R ⁴ , R ⁵ together with the atoms to which they are connected together form a 5-8 membered saturated and unsaturated ring, which can also optionally contains 0, 1 or 2 heteroatoms selected from N, O, S;

wherein, R ^a and R ^b each independently represent hydrogen, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl; or R ^a and R ^b together with the atoms to which they are attached form a 5-8 membered ring, and the ring may optionally contain 0, 1 or 2 heteroatoms selected from N, O and S;

where n represents 0, 1, 2 or 3.

Preferably, the compound of formula (I) has the following structure of formula (II):

in:

R ¹ , R ³ , R ⁴ , R ⁵ , R ^a , R ^b and n are as defined in claim 1;

R ² represents hydrogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, hydroxy (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl;

W represents CR ^L or N;

R ⁶ represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , - SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -P(O)R ^a R ^b ;

R ^L represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , - SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -P(O)R ^a R ^b ;

o means 0, 1, 2 or 3.

Preferably, the compounds of the present invention are selected from the following structures:

The compounds of the present invention can also be prepared in the form of pharmaceutically acceptable salts which can be formed using, for example, the following inorganic or organic acids: hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, acetic, glycolic acid , lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxy Benzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid.

The pharmaceutically acceptable salts of the present invention can be prepared by conventional methods, for example, by dissolving the compound of the present invention in a water-miscible organic solvent such as acetone, methanol, ethanol and acetonitrile, adding thereto an excess of an organic acid or Aqueous mineral acid solution to precipitate the salt from the resulting mixture, removing the solvent and remaining free acid therefrom, and isolating the precipitated salt.

The compounds of the present invention (or pharmaceutically acceptable salts thereof) may include the form of solvates, preferably, the solvates are hydrates.

The present invention also provides the use of the compounds of the present invention in the manufacture of a medicament for the prevention or treatment of diseases that can be modulated by inhibiting the activity of ALK5. Preferably, the disease is selected from cancer, tumor, inflammatory disease, autoimmune disease and immune-mediated disease.

Furthermore, the present invention provides a pharmaceutical composition for preventing or treating cancer, tumor, inflammatory disease, autoimmune disease, neurodegenerative disease, attention-related disease or immune-mediated disease, comprising the formula of the present invention (I) The compound as an active ingredient.

In addition, the present invention provides a method for preventing or treating cancer, tumors, inflammatory diseases, autoimmune diseases, neurodegenerative diseases, attention-related diseases A method of disease or immune-mediated disease comprising administering to a mammal in need thereof a compound of the present invention.

Representative examples of cancers or tumors may include, but are not limited to, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, neurocytoma, rectal cancer , colon cancer, familial adenomatous polyposis cancer, hereditary non-polyposis colorectal cancer, esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, medullary thyroid cancer, Papillary thyroid cancer, kidney cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, endometrial cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary cancer, melanoma, brain tumors such as glioblastoma, astrocytes Cytoblastoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (Diffuse large B-cell lymphoma) cell lymphomas, DLBCL), hepatocellular carcinoma, gallbladder carcinoma, bronchial carcinoma, small cell lung cancer, non-small cell lung cancer, multiple myeloma, basal cell tumor, teratoma, retinoblastoma, choroidal melanoma, spermatogonia cell tumor, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, sarcoma, liposarcoma, fibrosarcoma, Ewing's sarcoma, or plasmacytoma.

The compounds of the present invention or pharmaceutically acceptable salts thereof may provide enhanced anticancer effects when administered in combination with additional anticancer agents or checkpoint inhibitors for the treatment of cancer or tumors.

Representative examples of anticancer agents for treating cancer or tumors may include, but are not limited to, cell signaling inhibitors, chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan , carmustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, Gemcitabine, mercaptopurine, fludarabine, periwinkle, periwinkle, Vinorelbine, Paclitaxel, Docetaxel, Topotecan, Irinotecan, Etoposide, Trabectedin, Dactomycin, Doxorubicin, Epirubicin, Daunomycin, Mitoxantrone , bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonarelin analogues, megestrol, prednisone, dexamethasone, methylprednisolone, Thalidomide, interferon alfa, leucovorin, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, boron Tezomib, bosutinib, brinyb, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danucetib, dasatinib, multivitamin tinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motisanib, neratinib, nerotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, rosolitinib, Catinib, saridegib, sorafenib, sunitinib, tiratinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, velotinib Fini, vemodagi, volasertib, alemtuzumab, bevacizumab, belemtuzumab vedotin, catumuzumab, cetuximab, denosumab, gemtuzumab Anti-, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tositumumab, trastuzumab; checkpoint inhibitors, including but not Limited to anti-PD-1 antibody, anti-PD-L1 antibody, LAG3 antibody, TIM-3 antibody and anti-CTLA-4 antibody or any combination thereof.

Representative examples of inflammatory, autoimmune, and immune-mediated diseases may include, but are not limited to, arthritis, rheumatoid arthritis, spondyloarthritis, gouty arthritis, osteoarthritis, juvenile arthritis , other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related disorders, psoriasis, eczema, dermatitis, atopic dermatitis, pain, lung disease, lung inflammation, adult respiratory distress Acute respiratory distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (chronic obstructive pulmonary disease) Pulmonary Disease, COPD), cardiovascular disease, atherosclerosis, myocardial infarction, congestive heart failure, myocardial ischemia-reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome , Asthma, Sjögren's syndrome, autoimmune thyroid disease, urticaria (rubella), multiple sclerosis, scleroderma, organ transplant rejection, xenotransplantation, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease disease, Alzheimer's disease, diabetes-related diseases, inflammation, pelvic inflammatory disease, allergic rhinitis, allergic bronchitis, allergic sinusitis, leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, myeloma , acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, Multiple myeloma, myelodysplastic syndromes (Myelodysplastic syndromes, MDS), myeloproliferative neoplasms (Myeloproliferative neoplasm, MPN), diffuse large B-cell lymphoma and follicular lymphoma.

The compounds of the present invention, or pharmaceutically acceptable salts thereof, may provide enhancement when administered in combination with additional therapeutic agents useful in the treatment of inflammatory, autoimmune, and immune-mediated diseases therapeutic effect.

Representative examples of therapeutic agents for the treatment of inflammatory diseases, autoimmune diseases, and immune-mediated diseases may include, but are not limited to, steroidal drugs (eg, prednisone, prednisone, methylhydroponil) sone, cortisone, hydroxycortisone, betamethasone, dexamethasone, etc.), methotrexate, leflunomide, anti-TNFα agents (eg, etanercept, infliximab, adalix monoclonal antibodies, etc.), calcineurin inhibitors (eg, tacrolimus, pimecrolimus, etc.), and antihistamines (eg, diphenhydramine, hydroxyzine, loratadine, ebaz) Cetirizine, ketotifen, cetirizine, levocetirizine, fexofenadine, etc.), and at least one therapeutic agent selected from them may be included in the pharmaceutical composition of the present invention.

The compound of the present invention or a pharmaceutically acceptable salt thereof can be administered orally or parenterally as an active ingredient in an effective amount ranging from 0.1 to 2,000 mg/kg body weight/day, in mammals including humans (about 70 kg body weight), Preferably 1 to 1,000 mg/kg body weight/day, and administered in single or 4 divided doses per day, or on/off schedule. The dosage of the active ingredient can be adjusted according to a number of relevant factors, such as the condition of the item being treated, the type and severity of the disease, the rate of administration, and the opinion of the physician. In some cases, amounts less than the above doses may be appropriate. An amount greater than the above dose may be used if it does not cause adverse side effects and the amount may be administered in divided doses per day.

The pharmaceutical compositions of the present invention can be formulated according to any of conventional methods into dosage forms such as tablets, granules, powders, capsules, syrups for oral administration or parenteral administration (including intramuscular, intravenous and subcutaneous routes) , emulsion, microemulsion, solution or suspension.

Pharmaceutical compositions of the present invention for oral administration can be prepared by mixing the active ingredient with a carrier such as: cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, hard Magnesium fatty acid, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers and diluents. Examples of carriers employed in the injectable compositions of the present invention are water, saline solutions, dextrose solutions, dextrose-like solutions, alcohols, glycols, ethers (eg, polyethylene glycol 400), oils, fatty acids, fatty acid esters, Glycerides, surfactants, suspending and emulsifying agents.

Other features of this invention will become apparent in the course of describing exemplary embodiments of this invention, which are given to illustrate the invention and not to limit it, and the following examples were prepared using the methods disclosed in this invention. , isolation and characterization.

The compounds of the present invention can be prepared in a variety of ways known to those skilled in the art of organic synthesis, using synthetic methods known in the art of synthetic organic chemistry or by variations thereof known to those skilled in the art. The desired reactions can be carried out in solvents or solvent mixtures suitable for the kit materials used and for the transformation being effected.

After long-term and in-depth research, the present inventors discovered a class of heterocyclic compounds represented by formula (I) with TGF-β receptor inhibitory activity, especially ALK5 inhibitory activity. Based on the above findings, the inventors have completed the present invention.

the term

Unless otherwise stated, terms used in the present application, including the specification and claims, are defined as follows. It must be noted that in the specification and the appended claims, nouns modified by innumerable words generally include their plural meanings unless the context clearly dictates otherwise. If not stated otherwise, conventional methods of mass spectrometry, nuclear magnetic resonance (High performance liquid chromatography, HPLC), protein chemistry, biochemistry, recombinant DNA techniques and pharmacology were used.

In the specification and claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates in which such isomers exist. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the present invention. Numerous geometric isomers of C=C double bonds, C=N double bonds, ring systems, etc. may also exist in the compounds, and all of the above stable isomers are encompassed by the present invention. The present invention describes cis- and trans- (or E- and Z- ) geometric isomers of the compounds of the present invention, and which may be isolated as a mixture of isomers or as separate isomeric forms. The compounds of the present invention can be isolated in optically active or racemic forms. All methods used to prepare the compounds of the present invention and intermediates prepared therein are considered part of this invention. In the preparation of enantiomeric or diastereomeric products, they can be separated by conventional methods, eg by chromatography or fractional crystallization. Depending on the process conditions, the final product of the invention is obtained in free (neutral) or salt form. Both free forms and salts of these final products are within the scope of the present invention. If desired, one form of a compound can be converted into another. The free halide or acid can be converted into a salt; a salt can be converted into a free compound or another salt; a mixture of isomeric compounds of the present invention can be separated into individual isomers. The compounds of the present invention, their free forms and salts, may exist in various tautomeric forms in which hydrogen atoms are transposed to other parts of the molecule and the chemical bonds between the atoms of the molecule are thereby rearranged. It is to be understood that all tautomeric forms that may exist are encompassed by the present invention.

Unless otherwise defined, when a substituent is annotated as "optionally substituted", the substituent is selected from, for example, substituents such as alkyl, cycloalkyl, aryl, heterocyclyl, halogen, hydroxy, alkoxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amine groups (wherein 2 amino groups are substituted group is selected from the group consisting of alkyl, aryl or arylalkyl), alkanolamino, aralkylamino, aralkylamino, substituted alkylamino, substituted arylamino, substituted aralkylamino Amino, thio, alkylthio, arylthio, arylalkylthio, arylthiocarbonyl, arylalkylthiocarbonyl, alkylsulfonyl, arylsulfonyl, arylalkyl Sulfonyl, sulfonamido such as -SO ₂ NH ₂ , substituted sulfoamino, nitro, cyano, carboxyl, carbamate such as -CONH ₂ , substituted carbamate such as -CONH alkyl, - CONH aryl, -CONH arylalkyl or with two substituents on nitrogen selected from alkyl, aryl or arylalkyl, alkoxycarbonyl, aryl, substituted aryl, guanidino , Heterocyclyl such as indolyl, imidazolyl, furanyl, thienyl, thiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrrolidinyl, oxidyl, morpholinyl, oxazinyl, homoquanyl oxazinyl etc. and substituted heterocyclyl.

The terms "alkyl" or "alkylene" as used herein are intended to include branched or straight chain saturated aliphatic hydrocarbon groups having the indicated number of carbon atoms. For example, " _C1 - _C6 alkyl" means an alkyl group having 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (eg n-propyl and isopropyl), butyl (eg n-butyl, isobutyl, tert-butyl) and Pentyl (eg n-pentyl, isopentyl, neopentyl). Preferred alkyl groups are _C1 - _C6 alkyl groups, more preferred alkyl groups are _C1 - _C4 alkyl groups.

The term "alkenyl" refers to a straight or branched chain hydrocarbon group containing one or more double bonds and usually 2 to 20 carbon atoms in length. For example, "C2 _- C8 alkenyl" contains from two to _eight carbon atoms. Alkenyl groups include, but are not limited to, for example, vinyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like. Preferred alkenyl groups are C2 _{- C8} alkenyl groups, more preferred alkenyl groups are C2 _{- C6} alkenyl groups.

The term "alkynyl" refers to a straight or branched chain hydrocarbon group containing one or more triple bonds and usually 2 to 20 carbon atoms in length. For example, "C2 _- C8alkynyl" contains from two to _eight carbon atoms. Preferred alkynyl groups are C ₂ -C ₈ alkynyl groups, and more preferred alkenyl groups are C ₂ -C ₆ alkynyl groups. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.

The term "alkoxy" or "alkyloxy" refers to -O-alkyl. "C ₁ -C ₆ alkoxy" (or alkyloxy) is intended to include C ₁ , C ₂ , C ₃ , C ₄ , C ₅ and C ₆ alkoxy. Preferred alkoxy groups are C ₁ -C ₆ alkoxy groups, and more preferred alkoxy groups are C ₁ -C ₄ alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (eg, n-propoxy and isopropoxy), and t-butoxy. Similarly, "alkylthio" or "thioalkoxy" represents an alkyl group, as defined above, having the indicated number of carbon atoms attached through a sulfur bridge; eg, methyl-S- and ethyl-S-.

The term "carbonyl" refers to an organic functional group (C=O) composed of two atoms, carbon and oxygen, linked by a double bond.

The term "aryl", alone or as part of a larger moiety such as "aralkyl", "aralkoxy" or "aryloxyalkyl", refers to a single ring having a total of 5 to 12 ring members , bicyclic or tricyclic ring systems, wherein at least one ring in the system is aromatic and wherein each ring in the system contains from 3 to 7 ring members. Monocyclic aromatic group refers to phenyl group, bicyclic and more than bicyclic aromatic groups refer to naphthyl, anthracenyl, etc. At the same time, the aryl bicyclic ring can also be fused with a cycloalkyl group or a ring with a benzene ring. alkenyl, or fused to a cycloalkynyl. Preferred aryl groups are C ₆ -C ₁₂ aryl groups. In certain embodiments of the present invention, "aryl" refers to an aromatic ring system including, but not limited to, phenyl, biphenyl, indanyl, 1-naphthyl, 2-naphthyl, and tetrahydronaphthalene base. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Non-limiting examples include benzyl, phenethyl, and the like. A fused aryl group can be attached to another group at a suitable position on the cycloalkyl or aromatic ring. For example, an arrowed line drawn from a ring system indicates that the bond may be attached to any suitable ring atom.

The term "cycloalkyl" refers to a monocyclic or bicyclic cyclic alkyl group. A monocyclic cyclic alkyl group refers to a C3 _{- C8} cyclic alkyl group, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and norbornyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl". Bicyclic cyclic alkyl groups include bridged, spiro or fused ring cycloalkyl groups. Preferred cycloalkyls are C3 _{- C6} cycloalkyls.

The term "cycloalkenyl" refers to a monocyclic or bicyclic cyclic alkenyl group. _Monocyclic cyclic alkenyl refers to C3 _- C8 cyclic alkenyl, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and norbornyl. Branched cycloalkenyl groups such as 1-methylcyclopropenyl and 2-methylcyclopropenyl are included in the definition of "cycloalkenyl". Bicyclic cyclic alkenyl groups include bridged, spiro or fused ring cyclic alkenyl groups.

The term "hydroxyalkyl" refers to branched and straight chain saturated aliphatic hydrocarbon groups having the indicated number of carbon atoms with at least one -OH attached to the carbon atoms of the hydrocarbon group. Examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl.

"Halo" or "halogen" includes fluorine, chlorine, bromine and iodine. "Haloalkyl" is intended to include branched and straight chain saturated aliphatic hydrocarbon groups having the indicated number of carbon atoms and substituted with one or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoroethyl propyl and heptachloropropyl. Examples of haloalkyl groups also include "fluoroalkyl groups" which are intended to include branched and straight chain saturated aliphatic hydrocarbon groups having the indicated number of carbon atoms and substituted with one or more fluorine atoms.

"Haloalkoxy" or "haloalkyloxy" means a haloalkyl group, as defined above, having the indicated number of carbon atoms attached through an oxygen bridge. For example, "C ₁ -C ₆ haloalkoxy" is intended to include C ₁ , C ₂ , C ₃ , C ₄ , C ₅ , and C ₆ haloalkoxy. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluoroethoxy. Similarly, "haloalkylthio" or "thiohaloalkoxy" represents a haloalkyl group, as defined above, having the indicated number of carbon atoms attached through a sulfur bridge; eg, trifluoromethyl-S- and pentafluoroethyl -S-.

The term "heteroaryl" means a stable 3-, 4-, 5-, 6-, or 7-membered aromatic monocyclic or aromatic bicyclic or 7-, 8-, 9-, 10-, 11-, 12-membered , 13- or 14-membered aromatic polycyclic heterocycles, which are fully unsaturated, partially unsaturated, and which contain carbon atoms and 1, 2, 3, or 4 independently selected from N, O, and S and includes any of the following polycyclic groups in which any of the heterocycles defined above are fused to a benzene ring. Nitrogen and sulfur heteroatoms can optionally be oxidized. Nitrogen atoms are substituted or unsubstituted (ie, N or NR, where R is H or, if defined, another substituent). Heterocycles can be attached to their pendant groups at any heteroatom or carbon atom that results in a stable structure. The heterocyclyl groups described herein may be substituted on a carbon or nitrogen atom if the resulting compound is stable. The nitrogens in the heterocycle may be optionally quaternized. Preferably, when the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. Preferably, the total number of S and O atoms in the heterocycle is not greater than one. Preferred heteroaryl groups are 5-12 membered heteroaryl groups. Examples of heteroaryl groups include, but are not limited to, acridinyl, azetidinyl, acridine, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothienyl, benzoxazole base, benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, oxazolyl, 4aH - azolyl, quinolinyl, chromanyl, chromenyl, cinnoline, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3 -b] tetrahydrofuranyl, furanyl, furanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, imidazopyridyl, indolenyl, indolyl, indolyl Azinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquinoline olinyl, isothiazolyl, isothiazolopyridyl, isoxazolyl, isoxazolopyridyl, methylenedioxyphenyl, morpholinyl, naphthinyl, octahydroisoquinolinyl , oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridyl, oxazolidinyl, rylene, oxindole, pyrimidinyl, phenanthridine, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxthiyl, phenoxazinyl, phthalazinyl, oxazinyl, quaridinyl, oxidyl, 4-oxidyl, piperonyl, pteridyl, purinyl, pyridyl Ranyl, Pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolopyridyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinyl, 2-pyrrolidone, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinazinyl, quinoxalinyl, quinuclidinyl, tetrazolyl, Tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl , 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthryl, thiazolyl, thienyl, thiazolopyridyl, thienothiazolyl, thienooxazolyl, thiophene Imidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indoline, 1H-indazolyl, benzimidazolyl, 1 ,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydro-quinolinyl, 2,3-dihydro- Benzofuranyl, chromanyl, 1,2,3,4-tetrahydro-quinoxalinyl and 1,2,3,4-tetrahydro-quinazolinyl. The present invention also includes fused and spiro compounds containing, for example, the heterocycles described above.

The term "heterocycloalkyl" as used herein refers to a monocyclic heterocycloalkyl system, or a bicyclic heterocycloalkyl system, and also includes spiroheterocycles or bridged heterocycloalkyls. Monocyclic heterocycloalkyl refers to a 3-8 membered cyclic alkyl system containing at least one saturated or unsaturated but non-aromatic alkyl group selected from O, N, S, P. Bicyclic heterocycloalkyl systems refer to a heterocycloalkyl group fused to a phenyl group, or a cycloalkyl group, or a cycloalkenyl group, or a heterocycloalkyl group, or a heteroaryl group. Preferred heterocycloalkyl groups are 3-12 membered heterocycloalkyl groups.

The term "substituted" as used herein means that at least one hydrogen atom is replaced by a non-hydrogen group, provided that normal valences are maintained and the substitution results in a stable compound. As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (eg, C=C, C=N, or N=N).

Where nitrogen atoms such as amines are present on the compounds of the invention, these nitrogen atoms can be converted to N-oxides by treatment with oxidizing agents such as m -CPBA and/or hydrogen peroxide to obtain the compounds of the invention. other compounds. Accordingly, both shown and claimed nitrogen atoms are considered to encompass both the shown nitrogen and its N -oxides to obtain the derivatives of the invention.

When any variable occurs more than once in any composition or formula of a compound, its definition at each occurrence is independent of its definition at each other occurrence. Thus, for example, if a group is shown to be substituted with 0, 1, 2 or 3 R groups, the group may be optionally substituted with up to three R groups, and at each occurrence R is independently selected from the group consisting of R's definition. Furthermore, combinations of substituents and/or variables are only permissible if such combinations result in stable compounds.

The term "solvate" means a physical association of a compound of the present invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances, such as when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid, the solvate will be capable of isolation. Solvent molecules in a solvate may exist in regular and/or disordered arrangements. Solvates may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses both solution phase and isolatable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.

The term "patient" as used herein refers to an organism treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (eg, murine, simian/monkey, equine, bovine, porcine, canine, feline, etc.) and most preferably refer to humans.

As used herein, the term "effective amount" means the amount of a drug or agent (ie, a compound of the invention) that will elicit a biological or medical response, eg, in a tissue, system, animal or human being sought by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means an amount that results in improved treatment, cure, prevention or alleviation of a disease, disorder or side effect, or a reduction in the incidence of a disease, as compared to a corresponding subject not receiving such amounts or the rate of progression of the disease. An effective amount can be administered in one or more administrations, administrations or doses and is not intended to be limited by a particular formulation or route of administration. The term also includes within its scope an amount effective to enhance normal physiology.

As used herein, the term "treating" includes any effect that results in amelioration of a condition, disease, disorder, etc., eg, alleviation, reduction, modulation, amelioration or elimination, or amelioration of symptoms thereof. As used herein, a compound or pharmaceutical composition, upon administration, results in amelioration, especially improvement in severity, delay in onset, slow progression, or reduction in duration of a disease, symptom or condition. Whether fixed or temporary, continuous or intermittent, conditions may be attributable to or associated with the administration. The term "preventing" as used herein refers to preventing, blocking, eliminating the onset of a disease or interfering with or slowing the progression of a disease before it occurs.

The term "pharmaceutical composition" as used herein refers to the combination of an active agent with an inert or active carrier, making the composition particularly suitable for use in in vivo or ex vivo diagnosis or therapy. Examples of quiniums include, but are not limited to, alkali metal (eg, sodium) hydroxides, alkaline earth metal (eg, magnesium) hydroxides, ammonia, and the like. For therapeutic use, salts of compounds of the present invention For therapeutic use, salts of compounds of the present invention are intended to be pharmaceutically acceptable. However, non-pharmaceutically acceptable salts of acids and quiniums can also be used, for example, in the preparation or purification of pharmaceutically acceptable compounds.

The term "pharmaceutically acceptable" is used herein to refer to those compounds, substances, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissues without unduly toxic, irritating sexual, allergic reactions and/or other problems or complications and are commensurate with a reasonable benefit/risk ratio.

As used herein, the phrase "pharmaceutically acceptable carrier", "pharmaceutically acceptable carrier" means a pharmaceutical substance, composition or vehicle such as a liquid or solid filler, diluent, excipient, manufacturing aid ( such as lubricants, talc, magnesium stearate, calcium stearate or zinc stearate or stearic acid) or solvent encapsulating substances, which are involved in carrying or transporting the active compound from one organ or part of the body to another or body parts. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

Certain Pharmacy and Medical Terms

The term "acceptable", as used herein, refers to a formulation component or active ingredient that does not have undue deleterious effects on the health of the general target of treatment.

The term "cancer", as used herein, refers to an abnormal growth of cells that is uncontrollable and, under certain conditions, is capable of metastasizing (spreading). Cancers of this type include, but are not limited to, solid tumors (eg, bladder, bowel, brain, chest, uterus, heart, kidney, lung, lymphoid tissue (lymphoma), ovary, pancreas or other endocrine organs (eg, thyroid), prostate , skin (melanoma), or blood tumor (eg, nonleukemic leukemia).

The term "co-administration" or similar terms, as used herein, refers to the administration of several selected therapeutic agents to a patient, administered in the same or different administrations at the same or different times.

The term "enhancing" or "enhancing", as used herein, refers to the ability of a desired result to be increased or prolonged, either in potency or duration. Thus, in enhancing the therapeutic effect of a drug, the term "enhancer" refers to the drug's ability to increase or prolong the potency or duration of the drug in the system. As used herein, "potentiation value" refers to the ability to maximize the ability of another therapeutic agent in an ideal system.

The term "immune disease" refers to a disease or condition of an adverse or deleterious response to an endogenous or exogenous antigen. The result is usually the dysfunction of cells, or the destruction and dysfunction of the cells, or the destruction of organs or tissues that may produce immune symptoms.

The terms "kit" and "product packaging" are synonymous.

The term "subject" or "subject" includes mammals and non-mammals. Mammals include, but are not limited to, mammals: humans, non-human primates such as orangutans, apes and monkeys; agricultural animals such as cattle, horses, goats, sheep, pigs; livestock such as rabbits, dogs; laboratory animals including rodents, such as Rats, mice and guinea pigs, etc. Non-mammalian animals include, but are not limited to, birds, fish, and the like. In a preferred embodiment, the selected mammal is a human.

Route of administration

Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transdermal, vaginal, ear canal , nasal administration and topical administration. In addition, by way of example only, parenteral administration, including intramuscular Injection, subcutaneous injection, intravenous injection, intramedullary injection, ventricular injection, intraperitoneal injection, intralymphatic injection, and intranasal injection.

In one aspect, the compounds described herein are administered locally rather than systemically. In certain specific embodiments, the depot formulation is administered by implantation (eg, subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in another embodiment, the drug is administered by a targeted drug delivery system. For example, liposomes encapsulated by organ-specific antibodies. In this particular embodiment, the liposomes are selectively targeted to specific organs and absorbed.

Pharmaceutical composition and dosage

The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds of the present invention formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents, and optionally one or more of the other aforementioned therapeutic agent. The compounds of the present invention may be administered for any of the above uses by any suitable means, eg orally, such as tablets, pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups and emulsions; sublingual; buccal; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (eg, in the form of sterile injectable aqueous or non-aqueous solutions or suspensions ); nasally, including administration to nasal membranes, such as by inhalation spray; topical, such as in the form of a cream or ointment; or rectally, such as in the form of a suppository. They can be administered alone, but are usually administered using a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

Pharmaceutically acceptable carriers are formulated according to a number of factors within the purview of those skilled in the art. These factors include, but are not limited to: the type and nature of the active agent being formulated; the subject to which the composition containing the active agent is to be administered; the intended route of administration of the composition; and the therapeutic indication being targeted. Pharmaceutically acceptable carriers include aqueous and non-aqueous liquid media and various solid and semisolid dosage forms.

The above-mentioned carrier may include many different components and additives in addition to the active agent, and the above-mentioned other components are included in the formulation for various reasons well known to those skilled in the art, Examples are stabilized active agents, binders, and the like. A description of suitable pharmaceutical carriers and factors involved in carrier selection can be found in a number of readily available sources such as Allen L.V.Jr. et al. Remington: The Science and Practice of Pharmacy (2 Volumes), 22nd Edition (2012 ), Pharmaceutical Press.

Of course, dosage regimens for the compounds of the present invention will vary depending on known factors, such as the pharmacodynamic properties of the particular agent and its mode and route of administration; the recipient's species, age, sex, health, medical condition, and Weight; nature and extent of symptoms; type of concurrent treatment; frequency of treatment; route of administration, renal and hepatic function of the patient, and desired effect. According to general guidance, the daily oral dose of each active ingredient should be from about 0.001 mg/day to about 10-5000 mg/day, preferably from about 0.01 mg/day to about 1000 mg/day, and most preferably, when used for the indicated effect Typically from about 0.1 mg/day to about 250 mg/day. During constant rate infusion, the most preferred intravenous dose should be from about 0.01 mg/kg/minute to about 10 mg/kg/minute. The compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses of two, three or four times daily.

The compounds are usually in the form of suitable pharmaceutical diluents, excipients or carriers (herein) appropriately selected according to the intended form of administration (eg, oral tablets, capsules, elixirs and syrups) and consistent with conventional pharmaceutical practice. are administered in the form of a mixture of drug carriers).

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 mg to about 2000 mg of active ingredient per dosage unit. In these pharmaceutical compositions, the active ingredient will generally be present in an amount of about 0.1-95% by weight, based on the total weight of the composition.

A typical capsule for oral administration contains at least one compound of the invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture was passed through a 60 mesh screen and packaged into size 1 gelatin capsules.

A typical injectable formulation can be prepared by aseptically placing at least one compound of the invention (250 mg) in a vial, aseptically lyophilizing and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline to produce an injectable formulation.

Within the scope of the present invention are pharmaceutical compositions comprising, either alone or in combination with a pharmaceutical carrier, a therapeutically effective amount of at least one compound of the present invention as an active ingredient. Optionally, the compounds of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more other therapeutic agents (eg, anticancer agents or other pharmaceutically active substances).

Regardless of the route of administration chosen, the compounds of the present invention (which may be used in a suitable hydrated form) and/or the pharmaceutical compositions of the present invention are formulated into pharmaceutical dosage forms by conventional methods known to those skilled in the art .

The actual dosage level of the active ingredient in the pharmaceutical compositions of the present invention can be varied to obtain an amount of active ingredient that is effective in achieving the desired therapeutic response, composition and mode of administration for a particular patient, without being toxic to the patient.

The dose level selected will depend on a variety of factors, including the activity of the particular compound of the invention or its ester, salt or amide employed; the route of administration; the time of administration; the rate of excretion of the particular compound employed; the rate and extent of absorption; Duration of treatment; other drugs, compounds and/or substances used in combination with the particular compound used; age, sex, weight, condition, general health and previous medical history of the patient being treated, factors well known in the medical arts.

A physician or veterinarian having ordinary skill in the art can readily determine and prescribe an effective amount of the desired pharmaceutical composition. For example, in order to achieve the desired therapeutic effect, a physician or veterinarian may initiate a test of a compound of the present invention used in a pharmaceutical composition at a level below that required and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a compound of the present invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend on the factors discussed above. Typically, oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of the invention for patients will range from about 0.01 to about 50 mg/kg body weight/day. If desired, an effective daily dose of the active compound may be administered separately in two, three, four, five, six or more sub-doses at appropriate intervals throughout the day, optionally in unit dosage form. In certain aspects of the invention, the dosing is once a day.

Although the compounds of the present invention may be administered alone, it is preferred to administer the compounds in the form of a pharmaceutical formulation (composition).

Kit/Product Packaging

Kits/product packaging are also described herein for use in the treatment of the above-mentioned indications. These kits may consist of transporters, packs, or boxes of containers, which may be divided into compartments to accommodate one or more containers, such as vials, test tubes, and the like, each containing the method a single ingredient in . Suitable containers include bottles, vials, syringes and test tubes, among others. Containers are made of acceptable materials such as glass or plastic.

For example, the container may contain one or more of the compounds described herein, which may be present as pharmaceutical components or in admixture with other ingredients described herein. The container may have a sterile outlet (eg, the container may be an IV pack or bottle, the stopper being pierced by a hypodermic needle). Such kits may carry a compound, along with instructions for use, labeling, or operating instructions as described herein.

A typical kit may include one or more containers, each containing one or more materials (eg, reagents, or concentrated stock solutions, and/or instruments) to suit commercial promotion and user needs for the use of the compound. . These materials include, but are not limited to, buffers, diluents, filters, needles, syringes, dispensers, bags, containers, vials and/or tubes, with a list of contents and/or instructions for use, and instructions for the inner packaging. The entire set of instructions is to be included.

Labels can be displayed on or closely associated with the container. The presence of a label on a container means that the label letters, numbers or other features are affixed, molded, or engraved on the container; the label may also appear in a container box or shipping box containing a variety of containers, such as in product inserts. A label may be used to indicate a specific therapeutic use of the contents. The label may also indicate instructions for use of the contents, such as described in the above method.

All features described in this specification (including any stated claims, abstract and figures), and/or all steps involved in any method or process, may be present in any combination unless certain features or Steps are mutually exclusive in the same combination.

The above features mentioned in the present invention or the features mentioned in the embodiments can be combined arbitrarily. All the features disclosed in this specification can be used in combination with any composition, and each feature disclosed in the specification can be replaced by any alternative features that serve the same, equivalent or similar purpose. Therefore, unless otherwise stated, the disclosed features are only general examples of equivalent or similar features.

The present invention will be further described below in conjunction with specific embodiments. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. In the following examples, the experimental methods without specific conditions are usually in accordance with conventional conditions or in accordance with the conditions suggested by the manufacturer. All percentages, ratios, ratios, or parts are by weight unless otherwise indicated.

The unit in the weight volume percentage in the present invention is well known to those skilled in the art, for example, it refers to the weight of the solute in 100 ml of the solution. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described can be used in the methods of the present invention. Methods and materials for preferred embodiments described herein are provided for illustrative purposes only.

In a preferred example of the present invention, the following compounds are provided but not limited to:

The present invention will be further described below in conjunction with specific embodiments. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. In the following examples, the experimental methods without specific conditions are usually in accordance with conventional conditions, or in accordance with the conditions suggested by the manufacturer. Percentages and parts are by weight unless otherwise indicated.

specific embodiment

When preparative routes are not included, relevant intermediates are commercially available (eg from Sigma Aldrich, Alfa).

Generic process

Commercially available reagents were used without further purification. ¹ H-NMR spectra were recorded on a Bruker instrument at 500 MHz. Chemical shift values are expressed in parts per million, ie, delta values. The following abbreviations are used for the multiplicity of NMR signals: s=singlet, brs=broad, d=doublet, t=triplet, m=multiplet. Coupling constants are listed in J values, measured in Hz. NMR and mass spectral results were corrected for background peaks. Chromatography refers to column chromatography using 100 mesh silica gel and performed under nitrogen pressure (flash chromatography). TLC for monitoring the reaction refers to TLC performed using a specific mobile phase and silica gel F254 from Merck as the stationary phase.

LC-MS experiments were measured under the following conditions:

Instrumentation: Thermo U3000, ALLtech ELSD, MSQ, UV detector combined ELSD and MSD (efflux ratio 4:1). Column: Waters X-Bridge C-18, 3.5 μm, 4.6×50 mm; column temperature: 30°C. Gradient [time (min)/solvent B in A (%)]: 0.00/5.0, 0.70/95, 1.40/95, 1.41/5, 1.50/5. (Solvent A = 0.01% trifluoroacetic acid in water; Solvent B = 0.01% trifluoroacetic acid in acetonitrile). UV detection: 214/254/280/300nm; DAD detection: 200-400nm; flow rate: 4mL/min; MS: ESI, 100-1500m/z

Preparative HPLC typically uses an acidic method (gradient of acetonitrile and water, each containing 0.1% formic acid) with a Thermo U3000 AFC-3000; column: Globalsil C-18 12nm, 250 x 20mm, 10μm, or equivalent; flow rate: 20mL/min, to separate.

Synthesis of Intermediates

Preparation of compound INT-1 :

Under reflux conditions, the mixture of 4-fluoroacetophenone (2.5g, 18mmol) and N , N -dimethylformamide dimethyl acetal (2.4g, 20mmol) was stirred for 4 hours; the reaction solution was concentrated after , the crude product was dissolved in ethanol (10 mL), followed by the addition of hydrazine hydrate (1.1 g, 18 mmol, 80% w/w). The obtained reaction solution was stirred at 80° C. for 2 hours. After the reaction solution was concentrated, the obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1~1/1) to obtain yellow solid INT-1a (1.84 g, Yield: 62.7%). MS(ESI): m/z 163.2(M+H) ⁺ .

At room temperature, N -bromosuccinimide (549 mg, 3.1 mmol) was added to a solution of compound INT-1a (500 mg, 3.1 mmol) in N , N -dimethylformamide (5 mL) , the resulting reaction solution was stirred at the same temperature for 1.5 hours. The reaction solution was poured into water (50 mL) and extracted with ethyl acetate (50 mL×3); the combined organic phases were washed with water and saturated brine (100 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain INT-1b (553 mg, yield: 74.4%) as a white solid. ¹ H NMR (500 MHz, Chloroform- d ) δ 7.81-7.74 (m, 2H), 7.63 (s, 1H), 7.18-7.11 (m, 2H); MS (ESI): m/z 241.2 (M+H) ⁺ .

At 0°C, sodium hydrogen (38 mg, 0.95 mmol, 60% w/w in kerosene) was added to a solution of compound INT-1c (200 mg, 0.83 mmol) in anhydrous tetrahydrofuran (8 mL), and the resulting reaction solution was in The mixture was stirred under the same conditions for 20 minutes; then 2-(trimethylsilyl)ethoxymethyl chloride (207 mg, 1.24 mmol) was added, and the resulting reaction solution was further stirred at room temperature for 2 hours. The reaction solution was quenched with a little water, poured into water (50 mL), and extracted with ethyl acetate (50 mL×3); the combined organic phases were washed with water and saturated brine (100 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=10/1) to obtain INT-1 (298 mg, yield: 96.7%) as a colorless oil.

Preparation of compound INT-2 :

Cyclopropyl methyl ketone (160 mg, 1.9 mmol) was added to a solution of sodium hydrogen (37 mg, 1.6 mmol, 60% w/w in kerosene) in tetrahydrofuran (10 mL), and the resulting reaction was stirred at room temperature for half a It was heated to reflux after 1 hour; then a solution of 4-fluoroacetophenone (250 mg, 1.6 mmol) in tetrahydrofuran (3 mL) pre-dissolved was added dropwise. The resulting reaction solution was further stirred for half an hour under reflux. After cooling to room temperature, the reaction solution was poured into 1M aqueous hydrochloric acid solution to adjust pH to 7-8; and extracted with ethyl acetate (30 mL×2). The combined organic phases were washed with water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=20/1~10/1) to obtain INT-2a (250 mg, yield: 74.8%) as a pale yellow oil. MS(ESI): m/z 207.4(M+H) ⁺

Under reflux, a solution of compound INT-2a (250 mg, 1.2 mmol) and hydrazine hydrate (103 mg, 2.7 mmol, 80% w/w) in ethanol (5 mL) was stirred for 4 hours. The reaction solution was cooled to room temperature and concentrated. The obtained crude product was dissolved in dichloromethane (30 mL), washed with water and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a white solid INT-2b (200 mg, yield: 81.6%). MS(ESI): m/z 203.5(M+H) ⁺

Under ice bath condition, N -iodosuccinimide (270 mg, 1.2 mmol) was added to N , N -dimethylformamide (5 mL) dissolved with compound INT-2b (200 mg, 1.0 mmol) The resulting reaction solution was heated to 90°C and stirred for 16 hours. Dichloromethane and saturated sodium bicarbonate solution (30 mL each) were added to the reaction solution; the organic phase was washed with water and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to give a pale yellow oil INT-2c (300 mg, collected rate: 92.5%). MS(ESI): m/z 329.2(M+H) ⁺

Starting from compound INT-2c , referring to the last step in the synthesis of compound INT-1 , compound INT-2 is obtained. MS (ESI): m/z 459.1 (M+H) ⁺

Preparation of compound INT-3 :

From ethyl acetate and 4-fluoroacetophenone, the synthesis of reference compound INT-2a gave compound INT-3a .

From compound INT-3a , compound INT-3 is obtained by referring to the synthesis of compound INT-2 . MS (ESI): m/z 433.0 (M+H) ⁺ .

Preparation of compound INT-4 :

2,4-Dinitrophenylhydroxylamine (3.1 g, 15.4 mmol) was added to a solution of 4-(tert-butoxycarbonylamino)pyridine (3.0 g, 15.4 mmol) in 2-methyltetrahydrofuran (15 mL); The resulting reaction solution was stirred at 40°C for 4 hours, then cooled to room temperature and stirred overnight. The reaction solution was filtered to obtain yellow solid INT-4a (6.1 g, yield: 99.6%).

N , N -dimethylformamide (8 mL) was mixed with compound INT-4a (1.0 g, 2.5 mmol), ethyl propiolate (249 mg, 2.5 mmol) and potassium carbonate (703 mg, 5.0 mmol). Stir overnight at room temperature. The resulting reaction solution was poured into water (80 mL), and extracted with ethyl acetate (60 mL×3). The combined organic phases were washed with water and saturated brine (150 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain yellow solid INT-4b (378 mg, yield: 48.7%). MS(ESI): m/z 306.1(M+H) ⁺ .

A solution of compound INT-4b (378 mg, 1.24 mmol) and trifluoroacetic acid (1.41 g, 12.4 mmol) in dichloromethane (12 mL) was stirred at room temperature overnight. The obtained reaction solution was poured into water (30 mL), and extracted with dichloromethane (20 mL×2). The combined organic phases were washed with saturated sodium bicarbonate, water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated to give yellow solid INT-4c (254 mg, yield: 100%). MS(ESI): m/z 206.5(M+H) ⁺ .

Under ice bath conditions, sodium nitrite (128 mg, 1.86 mmol) was added to a solution of compound INT-4c (254 mg, 1.24 mmol) in aqueous hydrogen bromide (5 mL, 48% w/w), and maintained for 5 minutes; Cuprous bromide (355 mg, 2.48 mmol) was then added under the same conditions and maintained for a further 10 minutes. The obtained reaction solution was slowly heated and stirred to 50° C., and reacted for 20 minutes. The reaction solution was poured into water (20 mL) and extracted with ethyl acetate (30 mL×2). The combined organic phases were washed with saturated sodium bicarbonate, water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain INT-4 as a yellow solid (272 mg, yield: 81.7%). ¹ H NMR (500MHz, DMSO- d ₆ ) δ 8.86(d, J =7.5Hz, 1H), 8.48(s, 1H), 8.24-8.20(m, 1H), 7.34(d, J =7.5Hz, 1H), 4.32(q, J =7.0Hz, 2H), 1.34(t, J =7.0Hz, 3H); MS(ESI): m/z 269.3(M+H) ⁺ .

Preparation of compound INT-5 :

An aqueous sulfuric acid solution (40% w/w, 5 mL) in which compound INT-4 (100 mg, 0.37 mmol) was dissolved was stirred at 100° C. for 5 hours. The reaction solution was cooled to room temperature, poured into water (20 mL), and extracted with ethyl acetate (30 mL×2). The combined organic phases were washed with saturated sodium bicarbonate, water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain INT-5 (77 mg, yield: 94.6%) as a yellow oil. MS(ESI): m/z 197.3(M+H) ⁺ .

Preparation of compound INT-6 :

Under ice bath conditions, sodium hydrogen (72 mg, 1.8 mmol, 60% w/w in kerosene) was added to a solution of compound INT-1b (300 mg, 1.24 mmol) in tetrahydrofuran (8 mL) and maintained for 20 minutes; Iodomethane (353 mg, 2.5 mmol) was then added under the same conditions. The resulting reaction solution was slowly warmed to room temperature with stirring, and stirred at room temperature overnight. The reaction solution was quenched with a little water, poured into water (40 mL), and extracted with ethyl acetate (40 mL×2). The combined organic phases were concentrated and separated by preparative HPLC to obtain INT-6 as a yellow solid (149 mg, yield: 46.9%). ¹ H NMR (500MHz, Chloroform- d )δ 7.88-7.81(m,2H), 7.45(s,1H), 7.15-7.07(m,2H), 3.92(s,3H).

Preparation of compound INT-7 :

At 0°C, 1H-pyrazole-3-boronic acid pinacol (500 mg, 2.6 mmol) and N , N -diisopropylethylamine (333 mg, 2.6 mmol) were dissolved in dichloromethane (10 mL) The solution was stirred for half an hour before 2-(trimethylsilyl)ethoxymethyl chloride (430 mg, 2.6 mmol) was added. The reaction solution was slowly warmed to room temperature with stirring, and continued stirring at room temperature overnight. The reaction solution was diluted with dichloromethane (40 mL), washed with saturated sodium bicarbonate and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was separated by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain INT-7a (500 mg, yield: 59.8%) as a pale yellow oil.

Under nitrogen atmosphere, compound INT-7a (150 mg, 0.46 mmol), 2-bromo-6-methylpyridine (88 mg, 0.51 mmol), Pd(PPh ₃ ) ₄ (53 mg, 0.046 mmol) and potassium carbonate were mixed (192 mg, 1.38 mmol) of a mixed solution of 1,4-dioxane and water (3.3 mL, v/v=10/1) was stirred at 90° C. for 16 hours. The reaction solution was cooled, diluted with ethyl acetate (30 mL), and filtered through celite. The filtrate was concentrated and separated by silica gel column chromatography (petroleum ether/ethyl acetate=5/1) to obtain INT-7b (120 mg, yield: 89.6%) as a yellow oil. MS(ESI): m/z 290.5(M+H) ⁺

From compound INT-7b , compound INT-7 was obtained by referring to the synthesis of compound INT-1b . MS(ESI): m/z 368.3(M+H)+

Preparation of compound INT-8 :

Starting from compound INT-7a and 2-bromo-6-trifluoromethylpyridine, compound INT -8 was obtained by referring to the synthesis of compound INT-7 . MS(ESI): m/z 422.1(M+H) ⁺

Preparation of compound INT-9 :

Starting from compound INT-7a and 2-bromo-6-difluoromethylpyridine, compound INT-9 was obtained by referring to the synthesis of compound INT-7 . MS(ESI): m/z 404.1(M+H) ⁺

Preparation of compound INT-10 :

Compound INT-10 was obtained by referring to the synthesis of compound INT-2 from methyl 6-trifluoromethylpyridine-2-carboxylate. MS (ESI): m/z 510.2 (M+H) ⁺

Preparation of compound INT-11 :

Starting from methyl 6-methylpyridine-2-carboxylate, compound INT-11 was obtained by referring to the synthesis of compound INT-2 . MS(ESI): m/z 456.1(M+H) ⁺

Preparation of compound INT-12 :

Starting from 4-fluoroacetophenone and cyclopentanmethyl ketone, compound INT-12 was obtained by referring to the synthesis of compound INT-2 . MS(ESI): m/z 487.0(M+H) ⁺

Preparation of compound INT-13 :

From compound INT-4a and 3-alkynyl-2-butanone, compound INT-13 was obtained by referring to the synthesis of compound INT-4 . MS(ESI): m/z 239.0(M+H) ⁺

Preparation of compound INT-14 :

Diethyl oxalate (554 mg, 3.8 mmol) was added to a solution of sodium hydrogen (74 mg, 3.2 mmol, 60% w/w in kerosene) in tetrahydrofuran (20 mL), and the resulting reaction was stirred at room temperature for half an hour After heating to reflux; a solution of 4-fluoroacetophenone (500 mg, 3.6 mmol) in tetrahydrofuran (6 mL) was then added dropwise. The resulting reaction solution was further stirred for half an hour under reflux. After cooling to room temperature, the reaction solution was poured into 1M aqueous hydrochloric acid solution to adjust pH to 7-8; and extracted with ethyl acetate (30 mL×2). The combined organic phases were washed with water and saturated brine (50 mL each), dried over anhydrous sodium sulfate, and concentrated. The obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=20/1~10/1) to obtain INT-14a (386 mg, yield: 45.1%) as a pale yellow oil. MS (ESI): m/z 239.3 (M+H) ⁺

From compound INT-14a , compound INT-14 was obtained by referring to the synthesis of compound INT- 2 . MS(ESI): m/z 491.2(M+H) ⁺

Preparation of compound INT-15

Starting from 4-fluoroacetophenone and ethyl 1,1-difluoroacetate, compound INT-15 was obtained by referring to the synthesis of compound INT-14 . MS (ESI): m/z 469.4 (M+H) ⁺

Synthesis of Example Compounds

Example 1:

Under nitrogen atmosphere, compound INT-4 (10 mg, 37 μmol), pinacol diboronate (9.9 mg, 39 μmol), Pd(PPh ₃ ) ₂ Cl ₂ (2.6 mg, 3.7 μmol) and potassium acetate ( A solution of 10.9 mg, 111 μmol) in 1,4-dioxane (5 mL) was stirred at 90° C. for 2 hours. Then compound INT-1 (15 mg, 40 μmol), Pd(PPh ₃ ) ₄ (4.7 mg, 4.0 μmol) potassium phosphate (25.7 mg, 121 μmol) and water (0.5 mL) were added to the reaction solution; the resulting mixture was replaced with nitrogen three times and stirred overnight at 100°C under nitrogen atmosphere. The reaction solution was cooled to room temperature, filtered through celite, and concentrated. The obtained crude product was subjected to preparative thin layer chromatography (petroleum ether/ethyl acetate=3/1) to obtain a yellow oily substance 1a (16.7 mg, yield: 86.0%). MS(ESI): m/z 481.0(M+H) ⁺ .

A mixed solution (2 mL, v/v=1/1) of compound 1a (16.7 mg, 35 μmol) dissolved in trifluoroacetic acid and dichloromethane was stirred at room temperature for 2 hours. Ethyl acetate and water (15 mL each) were added to the reaction solution, followed by liquid separation; the organic phase was further washed with saturated sodium bicarbonate and saturated brine (10 mL each), and concentrated. The obtained crude product was separated by preparative HPLC to give 1 (2.0 mg, yield: 16.4%) as a white solid. ¹ H NMR (500MHz, DMSO- d 6) δ 13.33(s, 1H), 8.78(d, J =7.3Hz, 1H), 8.37(s, 1H), 7.84(s, 1H), 7.57-7.45(m ,3H),7.38-7.16(m,3H),7.09-7.02(m,1H),4.15(q, J =7.1Hz,2H),1.15(t, J =7.1Hz,3H); MS(ESI) : m/z 351.2(M+H) ⁺ .

Example 2:

From compound INT-5 , compound 2 was obtained by referring to the synthesis of compound 1 . ¹ H NMR (500MHz, DMSO- d 6)δ 13.25(s, 1H), 8.57(d, J =7.2Hz, 1H), 8.03(brs, 1H), 7.93(d, J =2.0Hz, 1H), 7.58-7.43(m,3H), 7.30-7.17(m,2H), 6.66-6.62(m,1H), 6.51-6.48(m,1H); MS(ESI): m/z 279.3(M+H) ⁺ .

Example 3:

Aqueous sodium hydroxide solution (3M, 1 mL) was added to a solution of compound 1a (147 mg, 0.31 mmol) in methanol (5 mL); the resulting reaction solution was stirred at 60°C for 2 hours. After the reaction solution was cooled to room temperature, the pH was adjusted to 3-4 with 1M aqueous hydrochloric acid, and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with saturated sodium bicarbonate and saturated brine (30 mL each), dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oil 3a (122 mg, yield: 88.1%). MS(ESI): m/z 453.2(M+H) ⁺ .

To a solution of compound 3a (122 mg, 0.27 mmol) in 1,4-dioxane (4 mL) was added N , N -diisopropylethylamine (70 mg, 0.54 mmol), HATU (123 mg, 0.32 mmol) and ammonia (0.4M in 1,4-dioxane, 5 mL); the resulting reaction was stirred at 50°C for 4 hours. The reaction solution was concentrated, and the obtained crude product was subjected to silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain a pale yellow oily substance 3b (100 mg, yield: 82.2%).

Starting from compound 3b , referring to the last step of compound 1 , compound 3 is obtained. ¹ H NMR (500MHz, Chloroform- d )δ 8.32-8.27(m,1H), 8.27-8.23(m,1H), 8.20(d, J =2.6Hz,1H), 7.84(brs,1H), 7.45- 7.37(m,2H), 7.28-7.24(m,2H), 7.09-7.00(m,2H), 6.71-6.65(m,1H); MS(ESI): m/z 322.3(M+H) ⁺ .

Example 4:

From compound INT-5 and compound INT-7 , compound 4 was obtained by referring to the synthesis of compound 2 . ¹ H NMR (500MHz, DMSO- d 6) δ 8.61-8.56(m, 1H), 8.30(s, 1H), 7.95(s, 1H), 7.81(s, 1H), 7.73(t, J =7.5Hz ,1H),7.27-7.22(m,1H),6.90-6.83(m,1H),6.53(s,1H),2.44(s,3H); MS(ESI): m/z 276.3(M+H) ⁺ .

Example 5:

From compound INT-5 and compound INT-8 , compound 5 was obtained by referring to the synthesis of compound 2 . ¹ H NMR (500MHz, DMSO- d 6) δ 8.57(d, J =7.5Hz, 1H), 8.22(s, 1H), 8.16(t, J =8.0Hz, 1H), 8.11(d, J =8.0 Hz, 1H), 7.98-7.94(m, 1H), 7.89-7.84(m, 2H), 6.89(d, J =7.5Hz, 1H), 6.50(s, 1H); MS(ESI): m/z 330.3(M+H) ⁺ .

Example 6:

From compound INT-4 and compound 6a , compound 6a was obtained by referring to the synthesis of compound 1a . MS(ESI): m/z 365.3(M+H) ⁺ .

From compound 6a , compound 6 was obtained by referring to the synthesis of compound 3b . ¹ H NMR (500MHz, DMSO- d 6)δ 8.67(d, J =7.1Hz,1H), 8.49(s,1H), 8.20(s,1H), 8.11(s,1H), 7.64(brs,1H) ), 7.51-7.41(m, 2H), 7.26-7.16(m, 2H), 7.03(brs, 1H), 6.78-6.72(m, 1H), 3.93(s, 3H); MS(ESI): m/ z 336.3(M+H) ⁺ .

Example 7:

From compound INT-4 and compound INT-2 , compound 7a was obtained by referring to the synthesis of compound 1a . MS(ESI): m/z 521.5(M+H) ⁺ .

From compound 7a , compound 7 was obtained by referring to the synthesis of compound 3 . ¹ H NMR (500MHz, DMSO- d 6) δ 12.88(brs,1H), 8.70(d, J =7.0Hz,1H), 8.52(s,1H), 8.20(s,1H), 7.69(s,1H) ), 7.48-7.38(m, 2H), 7.19(t, J =9.0Hz, 2H), 7.02(s, 1H), 6.81-6.73(m, 1H), 1.95-1.83(m, 1H), 0.98- 0.83 (m, 4H); MS (ESI): m/z 362.0 (M+H) ⁺ .

Example 8:

From compound INT-4 and compound INT-3 , compound 8 was obtained by referring to the synthesis of compound 7 . ¹ H NMR(500MHz,Methanol- d 4)δ 8.51(d, J =7.2Hz,1H),8.44(s,1H),8.15(s,1H),7.45-7.38(m,2H),7.07(s , 2H), 6.73(s, 1H), 4.62(s, 2H), 2.40(s, 3H); MS(ESI): m/z 336.2(M+H) ⁺ .

Example 9:

From compound INT-4 and compound INT-7 , compound 9 was obtained by referring to the synthesis of compound 7 . ¹ H NMR (500MHz, DMSO- d 6) δ 13.35(brs,1H), 8.66(s,1H), 8.48(s,1H), 8.40-8.24(m,1H), 7.73(t, J =7.5Hz ,1H),7.63(s,1H),7.22(s,1H),7.15-6.92(m,2H),2.39(s,3H); MS(ESI): m/z 319.1(M+H) ⁺ .

Example 10:

From compound INT-4 and compound INT-8 , compound 10 was obtained by referring to the synthesis of compound 7 . ¹ H NMR(500MHz, methanol- d 4)δ 8.51(d, J =7.0Hz,1H), 8.42(s,1H), 8.21(s,1H), 8.10-7.98(m,3H), 7.75-7.70 (m,1H),7.14(d, J =7.0Hz,1H); MS(ESI): m/z 373.2(M+H) ⁺ .

Example 11:

From compound INT-4 and compound INT-9 , compound 11 was obtained by referring to the synthesis of compound 7 . ¹ H NMR(500MHz,Methanol- d 4)δ 8.52(d, J =7.0Hz,1H),8.42(s,1H),8.38(s,1H),8.05(s,1H),8.00(t, J =8.0Hz, 1H), 7.90-7.83(m, 1H), 7.65(d, J =7.5Hz, 1H), 7.12-7.08(m, 1H), 6.65(t, J =45Hz, 1H); MS( ESI): m/z 355.0(M+H) ⁺ .

Example 12:

From compound INT-4 and compound INT-10 , compound 12 was obtained by referring to the synthesis of compound 7 . ¹ H NMR(500MHz,Methanol- d 4)δ 8.54(d, J =7.5Hz,1H),8.45(s,1H),8.27(s,1H),7.98(t, J =7.5Hz,1H), 7.65(d, J =7.5Hz,1H), 7.04-6.99(m,1H), 2.02-1.93(m,1H), 1.04-0.95(m,2H), 0.91-0.85(m,2H); MS( ESI): m/z 413.3(M+H) ⁺ .

Example 13:

From compound INT-4 and compound INT-11 , compound 13 was obtained by referring to the synthesis of compound 7 . ¹ H NMR(500MHz, Methanol- d 4)δ 8.70-8.42(m, 2H), 8.33(s, 1H), 7.72-7.55(m, 1H), 7.49-7.07(m, 2H), 7.01-6.85( m,1H), 2.59-2.30(m,3H), 2.09-1.81(m,1H), 1.08-0.85(m,4H); MS(ESI): m/z 359.3(M+H) ⁺ .

Example 14:

Starting from compound INT-4 and compound INT-10 , referring to the synthesis of compound 12 , compound 14 was obtained by replacing ammonia with dimethylamine. ¹ H NMR(500MHz, Methanol- d 4)δ 8.53(s,1H), 8.26(s,1H), 8.12-7.93(m,3H), 7.64(s,1H), 7.03-7.00(m,1H) ,3.20(s,6H),2.05-1.97(m,1H),1.05-0.95(m,2H),0.92-0.85(m,2H); MS(ESI): m/z 441.2(M+H) ⁺ .

Example 15:

Starting from compound INT-4 and compound INT-10 , referring to the synthesis of compound 12 , ammonia was replaced with methylamine to obtain compound 15 . ¹ H NMR(500MHz, Methanol- d 4)δ 8.52(s, 1H), 8.36(s, 1H), 8.27(s, 1H), 8.06-7.94(m, 2H), 7.64(d, J=7.5Hz) ,1H),7.00(dd,J=7.0,2.0Hz,1H),2.90(s,3H),1.99(s,1H),1.00(s,2H),0.91-0.84(m,2H); MS( ESI): m/z 427.2(M+H) ⁺ .

Example 16:

Starting from compound INT-4 and compound INT-2 , referring to the synthesis of compound 7 , ammonia was replaced with ethanolamine to obtain compound 16 . ¹ H NMR(500MHz,Methanol- d 4)δ 8.50(d,J=7.0Hz,1H),8.42(s,1H),8.31(s,1H),7.44-7.39(m,2H),7.08(t ,J=8.5Hz,2H),6.78(d,J=7.0Hz,1H),3.71(t,J=6.0Hz,2H),3.49(t,J=6.0Hz,2H),2.04-1.96(m ,1H),1.05-0.96(m,2H),0.92-0.85(m,2H); m/z 405.7(M+H) ⁺ .

Example 17:

From compound INT-4 and compound INT-2 , compound 17 was obtained by referring to the synthesis of compound 7 . ¹ H NMR(500MHz, Methanol- d 4)δ 8.51(d,J=7.0Hz,1H),8.44(s,1H),8.17(s,1H),7.42-7.38(m,2H),7.05(t ,J=8.5Hz,2H),6.73(d,J=8.0Hz,1H),2.13-2.01(m,2H),1.89-1.71(m,5H),1.71-1.63(m,2H); m/ z 389.7(M+H) ⁺ .

Example 18:

From compound INT-13 and compound INT-2 , compound 18 was obtained by referring to the synthesis of compound 1 . ¹ H NMR(500MHz,Methanol- d 4)δ 8.60(d,J=7.2Hz,1H),8.55(s,1H),8.38(s,1H),7.42(m,2H),7.15-7.05(m ,2H),6.96(s,1H),2.55(s,3H),2.12-1.96(m,1H),0.99(m,4H); m/z 361.2(M+H) ⁺ .

Example 19:

Starting from compound 7a , referring to the last step in the synthesis of compound 1 , compound 19a was obtained. m/z 391.2(M+H) ⁺ .

In an ice bath, diisobutylaluminum hydride (83 μL, 2M in toluene) was added dropwise to a solution of compound 19a (40 mg, 0.10 mmol) in dichloromethane (1 mL); the resulting mixture was in the same Stir for half an hour. The reaction solution was then added to potassium sodium tartrate solution (5 mL, 1M aqueous solution), extracted with ethyl acetate; after the organic phase was concentrated under reduced pressure, the obtained crude product was separated by preparative HPLC to obtain white solid 19 (5.2 mg, yield: 14.6%) . ¹ H NMR(500MHz,Methanol- d 4)δ 8.44(d,J=7.2Hz,1H),7.95(s,1H),7.70(s,1H),7.44(dd,J=8.5,5.4Hz,2H ), 7.08(m, 2H), 6.71(m, 1H), 4.76(s, 2H), 2.01(m, 1H), 0.94(m, 4H); m/z 349.3(M+H) ⁺ .

Example 20:

From compound INT-14 and compound INT-4 , compound 20a was obtained by referring to the synthesis of compound 1 and compound 3 . m/z 394.3(M+H) ⁺ .

Starting from compound 20a , compound 20 was synthesized with reference to the last step of compound 19 . ¹ H NMR(500MHz, Methanol- d 4)δ 13.31(s,1H),8.69(d,J=7.0Hz,1H),8.53-8.48(m,1H),8.09(s,1H),7.49-7.38 (m,2H), 7.29-7.13(m,2H), 7.01-6.75(m,1H), 4.49(s,2H); m/z 352.2(M+H) ⁺ .

Example 21:

From compound INT-15 and compound INT-4 , compound 21 was obtained by referring to the synthesis of compound 1 and compound 3 . ¹ HNMR(500MHz,Methanol- d 4)δ 8.56(d,J=7.0Hz,1H),8.44(s,1H),8.23(s,1H),7.42(dd,J=8.5,5.0Hz,2H) ,7.13(t,J=8.5Hz,2H),6.90-6.83(m,1H),1.36-1.19(m,1H); m/z 372.3(M+H) ⁺ .

Test Example

Determination of Inhibitory Effect of Compounds on TGFβRI Kinase (ALK5) Activity:

TGFβRI kinase was purchased from Carna (Cat # 09-141). To a 384-well plate (Greiner, Cat #784075) was added 2 μl of enzyme solution (TGFβRI kinase 25 nM in the final reaction) in kinase buffer (40 mM Tris pH 7.5, 20 mM MgCl ₂ , 1 mM DTT, 1 mg/ml BSA) ). For negative controls 2 μl of kinase buffer was added. Compounds were prepared as 10 mM stock solutions in DMSO, and compounds were diluted a second time in DMSO as needed for the starting concentration prior to assaying the compound. 2.5 μl of compound was added into 47.5 μl of ddH ₂ O, and diluted according to the 3-fold dilution method, and 10 concentration points were set for each compound. After compound dilution was completed, 1 μl was added to the enzyme solution. After thorough mixing, incubate at room temperature for 10 min (the DMSO concentration in the final reaction system is 1%). For negative and positive controls, 1 μl of 5% DMSO in water was added. Finally, 2 μl of a mixture containing ATP and TGFβRI kinase polypeptide substrate (Signalchem, Cat # T36-58) was added (the final concentration of ATP was 3.5 μM, and the final concentration of substrate was 0.1 μg/ul), and the mixture was thoroughly mixed and placed at 28°C. The reaction was carried out for 120 min. Finally, the ADP-Glo Kinase Assay Kit (Promega, Cat # V9102) was used for detection. The final chemiluminescent signal was read using Molecular Devices, SpectraMax i3x. A 4-parameter curve fit was performed on the obtained data using XLFIT and _IC50 was calculated.

Determination of the inhibitory effect of compounds on p38α kinase activity:

p38α kinase was purchased from SignalChem (Cat # M39-10BG). Add 2 μl of enzyme solution (p38α kinase in the final reaction) in kinase buffer (40 mM Tris pH 7.5, 20 mM MgCl ₂ , 0.05 mM DTT, 0.1 mg/ml BSA) in a 384-well plate (Greiner, Cat #784075). is 0.8ng/ul). For negative controls 2 μl of kinase buffer was added. Compounds were prepared as 10 mM stock solutions in DMSO, and compounds were diluted a second time in DMSO as needed for the starting concentration prior to assaying the compound. 2.5 μl of compound was added into 47.5 μl of ddH ₂ O, and diluted according to the 3-fold dilution method, and 10 concentration points were set for each compound. After compound dilution was completed, 1 μl was added to the enzyme solution. After thorough mixing, incubate at room temperature for 10 min (the DMSO concentration in the final reaction system is 1%). For negative and positive controls, 1 μl of 5% DMSO in water was added. Finally, 2 μl of a mixture containing ATP and p38 kinase polypeptide substrate (Signalchem, Cat #P03-58) was added (the final concentration of ATP was 50 μM, and the final concentration of the substrate was 0.125 μg/μl), and the mixture was thoroughly mixed and placed at 25 degrees for reaction 120min. Finally, the ADP-Glo Kinase Assay Kit (Promega, Cat # V9102) was used for detection. The final chemiluminescent signal was read using Molecular Devices, SpectraMax i3x. A 4-parameter curve fit was performed on the obtained data using XLFIT and _IC50 was calculated.

Results of the inhibition of the kinase activity of ALK5 and p38α by the compounds listed in the Examples:

Determination of Inhibitory Activity of Compounds on TGFβRI Receptor Smad Signaling Pathway:

HEK-Blue TGFβ cells (Invivogen, Cat# hkb-tgfb) were collected and adjusted to a cell density of 1.25×10 ⁶ cells/ml with 10% FBS in DMEM, and 40 μl per well was added to a 96-well plate. Compounds were prepared as 10 mM stock solutions in DMSO, and compounds were diluted a second time in DMSO as needed for the starting concentration prior to assaying the compound. 2.5 μl of compound was added to 1 ml of complete medium, mixed by pipetting, and the compound was diluted 3-fold with DMEM medium containing 0.25% DMSO (the concentration of DMSO in 100 μl system was 0.1%). Take 40 μl of the prepared compound into a 96-well cell plate, add 40 μl of medium containing 0.25% DMSO to the positive control and negative control, and incubate in a 37°C 5% CO ₂ incubator for 2 hours. 20 μl of human recombinant TGFβ1 (Invivogen, cat#Rcyc-htgfb1) was added to each well at a final concentration of 0.1 ng/ml. Incubate for 24 hours at 37°C in 5% CO ₂ . 24 hours later, 60 μl of the supernatant was taken for secreted alkaline phosphatase (SEAP) detection, and 60 μl/well of medium was added to the cell plate for cell activity detection. The SEAP assay was performed with the Great EscApe SEAP chemiluminescence KIT (Clontech, Cat#631738), and the cell viability assay was performed with the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat# G7573). The final chemiluminescent signal was read using Molecular Devices, SpectraMax i3x. A 4-parameter curve fit was performed on the obtained data using XLFIT and _IC50 was calculated.

Results of the inhibitory activity of the compounds listed in the Examples on the TGFβRI receptor Smad signaling pathway:

Claims (8)

A compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof, wherein said compound of formula (I) has the following structure:

Wherein, Cy represents a C ₆ -C ₁₀ aryl group or a 5-10-membered heteroaryl group substituted by 0, 1, 2, and 3 substituents, wherein the substituents are selected from: halogen, C ₁ -C ₆ Alkyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -P(O)R ^a R ^b ; R ¹ represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ ring Alkyl, hydroxyl (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl; R ² represents hydrogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, hydroxyl (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O ) OR ^a , -C(O)NR ^a R ^b , -NR ^a C(O) R ^b , -SO ₂ NR ^a R ^b , -NR ^a SO ₂ R ^b ; R ³ represents hydrogen, halogen, C ₁ - C ₆ alkyl, C ₃ -C ₆ cycloalkyl, hydroxy (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -NR ^a C(O)R ^b , -SO ₂ NR ^a R ^b , -NR ^a SO ₂ R ^b ; R ⁴ represents hydrogen, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , hydroxyl (C ₁ -C ₆ alkyl); R ⁵ represents hydrogen, C ₁ -C ₆ alkane base, C _2- C ₆ alkenyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl; or R ⁴ , R ⁵ together with the atoms to which they are attached form a 5-8 membered saturated or unsaturated ring, the ring may optionally contain 0, 1 or 2 heteroatoms selected from N, O, S; wherein, R ^a and R ^b each independently represent hydrogen, C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl; or R ^a , R ^b and the atoms to which they are attached together form a 5-8-membered ring, which can also Optionally contains 0, 1 or 2 heteroatoms selected from N, O, S; n represents 0, 1, 2 or 3. The compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt or isomer thereof, wherein the compound of formula (I) has the following structure of formula (II):

wherein, R ¹ , R ³ , R ⁴ , R ⁵ , R ^a , R ^b and n have the definitions as described in claim 1; R ² represents hydrogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ ring Alkyl, hydroxy (C ₁ -C ₆ alkyl), halogenated C ₁ -C ₆ alkyl; W represents CR ^L or N; R ⁶ represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O)NR ^a R ^b , -P(O)R ^a R ^b ; wherein, ^RL represents hydrogen, halogen, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, halogenated C ₁ -C ₆ alkyl, -OR ^a , cyano, nitro, NR ^a R ^b , -SO ₂ R ^a , -C(O)R ^a , -C(O)OR ^a , -C(O) NR ^a R ^b , -P(O)R ^a R ^b ; wherein o represents 0, 1, 2 or 3. The compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof according to any one of claims 1-2, wherein the compound of formula (I) is selected from:

A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or isomer thereof, and an optional pharmaceutically acceptable carrier. The pharmaceutical composition of claim 4, further comprising additional therapeutic agents and/or Checkpoint inhibitor, the additional therapeutic agent is preferably selected from the group consisting of chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinca Chlorine, Vinorelbine, Vinorelbine, Paclitaxel, Docetaxel, Topotecan, Irinotecan, Etoposide, Trabectedin, Dactomycin, Doxorubicin, Epirubicin, Daunomycin pyridoxine, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonarelin analogs, megestrol, prednisone, dexamethasone Metasone, methylprednisolone, thalidomide, interferon alfa, calcium folinate, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, britinib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danucetib, Dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motisanib, neratinib, nerotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, Roxolitinib, cicatinib, saridegib, sorafenib, sunitinib, tiratinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, vitamin Lipanib, vemurafenib, vemodagi, volasertib, alemtuzumab, bevacizumab, belemumab vedotin, catulumumab, cetuximab, denosumab anti, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tositumumab, trastuzumab; described The checkpoint inhibitor is preferably selected from anti-PD-1 antibody, anti-PD-L1 antibody, LAG3 antibody, TIM-3 antibody and anti-CTLA-4 antibody. The compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof according to any one of claims 1-3 or the pharmaceutical composition according to any one of claims 4-5 is prepared for use by Use in a medicament for inhibiting TGF-beta receptors for the prevention or treatment of tumors, viral infections, organ transplant rejection, neurodegenerative diseases, attention deficit related disorders or autoimmune diseases, Wherein the TGF-beta receptor is preferably selected from the TGFbetaRI (ALK5) receptor. The use according to claim 6, wherein the tumor is selected from skin cancer, bladder cancer, ovarian cancer, breast cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, neurocytoma , rectal cancer, colon cancer, familial adenomatous polyposis cancer, hereditary nonpolyposis colorectal cancer, esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, thyroid medullary cancer cancer, papillary thyroid cancer, kidney cancer, renal parenchymal cancer, cervical cancer, endometrial cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary cancer, melanoma, brain tumors such as glioblastoma, astrocytes Cytocytoma, Meningioma, Medulloblastoma and Peripheral Neuroectodermal Tumors, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Acute Lymphatic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gallbladder carcinoma, bronchial carcinoma, small cell Lung cancer, non-small cell lung cancer, multiple myeloma, basal cell tumor, teratoma, retinoblastoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, sarcoma, liposarcoma, Fibrosarcoma, Ewing's sarcoma, and plasmacytoma. The use according to claim 6, wherein the tumor is choroidal melanoma.